Income Statement
CRESCENT BIOPHARMA, INC.
CBIO
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
10.84 | - | - | - | - | - | - | - | - | 0.02 | 20.07 | 15.03 |
|
Cost of Revenue
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Gross Profit
|
10.84 | - | - | - | - | - | - | - | - | 0.02 | 20.07 | 15.03 |
|
Operating Expenses
|
163.48 | 40.04 | 39.29 | 47.48 | 64.61 | 61.67 | 61.39 | 51.50 | 33.93 | 31.93 | 32.86 | 26.17 |
|
Research & Development
|
138.09 | 14.26 | 20.07 | 28.39 | 47.49 | 44.93 | 47.03 | 40.09 | 24.10 | 23.28 | 25.05 | 19.57 |
|
Selling, General & Administrative
|
25.39 | 18.25 | 19.21 | 19.09 | 17.12 | 16.74 | 14.36 | 11.41 | 9.83 | 8.65 | 7.81 | 6.60 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Operating Income
|
-152.63 | -40.04 | -39.29 | -47.48 | -64.61 | -61.67 | -61.39 | -51.50 | -33.93 | -31.91 | -12.78 | -11.14 |
|
Non-Operating Income
|
-0.69 | 2.16 | - | - | - | - | - | - | - | - | - | - |
|
Interest Income
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Interest Expense
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | - | - | - | - | - | 0.65 | 0.10 | 0.02 | 0.02 |
|
Income Before Tax
|
-151.94 | - | - | - | - | - | - | - | - | - | - | - |
|
Income Tax Expense
|
2.00 | - | - | - | - | - | - | - | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Net Income
|
-153.94 | -37.88 | -36.90 | -46.69 | -63.43 | -51.03 | -57.89 | -48.27 | -33.28 | -31.81 | -12.77 | -11.12 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
-152.63 | -40.04 | -39.29 | -47.48 | -64.61 | -61.67 | -61.39 | -51.50 | -33.93 | -31.91 | -12.78 | -11.14 |
|
Earnings Per Share (Basic)
|
- | -0.59 | -0.58 | -0.89 | -1.23 | - | - | - | - | - | - | -0.60 |
|
Diluted EPS
|
- | -0.59 | -0.58 | -0.89 | -1.23 | - | - | - | - | - | - | -0.60 |
|
Weighted Average Shares
|
- | 64.48 | 63.34 | 52.53 | 51.45 | - | - | - | - | - | - | 18.45 |
|
Diluted Weighted Avg Shares
|
- | 64.48 | 63.34 | 52.53 | 51.45 | - | - | - | - | - | - | 18.45 |
|
Comprehensive Income
|
-153.94 | - | - | - | - | - | - | - | - | - | - | - |